Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Lindsey Elizabeth RoekerTatyana A FeldmanJacob D SoumeraiVictoria FalcoGail PantonColleen DorseyAndrew D ZelenetzLorenzo FalchiJae H ParkDavid J StrausCamila Pena VelasquezSonia LebowitzYehudit FoxKristen BattiatoCarissa LaudatiMeghan C ThompsonElizabeth McCarthySabrina KdiryRosalba MartignettiTeja TurpuseemaMichelle PurdomDana PaskalisHari P MiskinPeter SportelliLori A LeslieAnthony R MatoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This triplet approach utilizes the addition of U2 to ibrutinib as an MRD-driven time-limited therapy. This therapy was well tolerated and effective. TFO following this therapy appears durable in ongoing follow-up.